

L9 ANSWER 1 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:38104 USPATFULL  
 TITLE: VEGF fusion proteins  
 INVENTOR(S): Kovesdi, Imre, Rockville, MD, UNITED STATES  
 Kessler, Paul D., Frederick, MD, UNITED STATES  
 PATENT ASSIGNEE(S): GenVec, Inc., Gaithersburg, MD, UNITED STATES, 20878  
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027751	A1	20030206
APPLICATION INFO.:	US 2001-832355	A1	20010410 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH STETSON AVENUE, CHICAGO, IL, 60601-6780		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1		
LINE COUNT:	7034		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides therapeutic fusion proteins which include a first peptide portion comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. Further provided are polynucleotides encoding such fusion proteins, vectors including such polynucleotides, methods of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing using such proteins, polynucleotides, and vectors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:24164 USPATFULL  
 TITLE: Compositions and methods for inducing gene expression  
 INVENTOR(S): Gregory, Richard J., Westford, MA, UNITED STATES  
 Vincent, Karen, Arlington, MA, UNITED STATES  
 PATENT ASSIGNEE(S): Genzyme Corporation, Cambridge, MA, UNITED STATES,  
 02139 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018007	A1	20030123
APPLICATION INFO.:	US 2002-190394	A1	20020703 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-579897, filed on 26 May 2000, GRANTED, Pat. No. US 6432927 Continuation-in-part of Ser. No. US 1998-133612, filed on 13 Aug 1998, ABANDONED Continuation of Ser. No. WO 1998-US25753, filed on 4 Dec 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67546P	19971204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENZYME CORPORATION, LEGAL DEPARTMENT, 15 PLEASANT ST CONNECTOR, FRAMINGHAM, MA, 01701-9322	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 2021

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2002:273361 USPATFULL

TITLE: Use of lymphangiogenic agents to treat lymphatic disorders

INVENTOR(S): Gravereaux, Edwin C., Brookline, MA, UNITED STATES  
Silver, Marcy, Bolton, MA, UNITED STATES  
Yoon, Young-Sup, Watertown, MA, UNITED STATES  
Isner, Jeffrey M., Weston, MA, UNITED STATES

PATENT ASSIGNEE(S): Isner, Linda, Weston, MA, UNITED STATES LR  
St. Elizabeth's Medical Center of Boston, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151489	A1	20021017
APPLICATION INFO.:	US 2001-970088	A1	20011002 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-237171P	20001002 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David G. Conlin, Dike, Bronstein, Roberts & Cushman, Intellectual Property Practice Group, P. O. Box 9169, Boston, MA, 02209	

NUMBER OF CLAIMS: 41  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 35 Drawing Page(s)  
LINE COUNT: 1803

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for promoting the growth of new lymph vessels (lymphangiogenesis). Generally, such methods include administering at least one vascular endothelial factor (VEGF) such as VEGF-2. In one embodiment, therapeutic methods for treating lymphedema and related disorders in a human patient are disclosed. The VEGF can be provided by any suitable means including direct injection of a nucleic acid encoding same or an active fragment thereof. Also provided are pharmaceutical products for promoting lymphangiogenesis as well as a test system for screening compounds capable of inducing new lymph vessel growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2002:202067 USPATFULL  
 TITLE: Compositions and methods for inducing gene expression  
 INVENTOR(S): Gregory, Richard J., Westford, MA, United States  
 Vincent, Karen, Arlington, MA, United States  
 PATENT ASSIGNEE(S): Genzyme Corporation, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6432927	B1	20020813
APPLICATION INFO.:	US 2000-579897		20000526 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 133612		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67546P	19971204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Nguyen, Dave T.	
LEGAL REPRESENTATIVE:	Kanter, Madge R.	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	2175	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 7 PCTFULL COPYRIGHT 2004 Univentio on STN  
 ACCESSION NUMBER: 2002029087 PCTFULL ED 20020627 EW 200215  
 TITLE (ENGLISH): USE OF LYMPHANGIOGENIC AGENTS TO TREAT LYMPHATIC DISORDERS  
 TITLE (FRENCH): UTILISATION D'AGENTS LYMPHANGIOGENIQUES POUR LE TRAITEMENT DE TROUBLES LYMPHATIQUES  
 INVENTOR(S): GRAVEREAUX, Edwin, C., 1212 Fifth Avenue, #13E, New York, NY 10029, US;  
 MARCY, Silver, 438 Still River Road, Bolton, MA 01740, US;  
 ISNER, Jeffrey, M., 34 Brenton Road, Weston, MA 02193, US;  
 YOON, Young-sup, 275 Main Street, Apt. #605, Watertown, MA 02472, US  
 PATENT ASSIGNEE(S): ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC., 736 Cambridge Street, Boston, MA 02135, US [US, US]  
 AGENT: BUCHANAN, Robert, L.\$, Dike, Bronstein, Roberts & Cushman - IP Practice Group of Edwards & Angell, LLP, P.O. Box 9169, Boston, MA 02209\$, US  
 LANGUAGE OF FILING: English

LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002029087	A2	20020411

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL  
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG  
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
TM TR TT TZ UA UG UZ VN YU ZA ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-US30904 A 20011002

PRIORITY INFO.:

US 2000-60/237,171 20001002

ABEN

The present invention provides methods for promoting the growth of new lymph vessels (lymphangiogenesis). Generally, such methods include administering at least one vascular endothelial factor (VEGF) such as VEGF-2. In one embodiment, therapeutic methods for treating lymphedema and related disorders in a human patient are disclosed. The VEGF can be provided by any suitable means including direct injection of a nucleic acid encoding same or an active fragment thereof. Also provided are pharmaceutical products for promoting lymphangiogenesis as well as a test system for screening compounds capable of inducing new lymph vessel growth.

ABFR

L'invention concerne des methodes permettant de favoriser la croissance de nouveaux vaisseaux lymphatiques (lymphangiogenese). D'une maniere generale, de telles methodes consistent a administrer au moins un facteur endothelial vasculaire (VEGF) tel que VEGF-2. Dans un mode de realisation, l'invention concerne des methodes therapeutiques permettant de traiter un lymphoedeme et des troubles associes chez un patient humain. Le VEGF peut etre administre par un moyen approprie quelconque, notamment une injection directe d'un acide nucleique codant celui-ci ou un fragment actif de celui-ci. L'invention concerne en outre des produits pharmaceutiques favorisant la lymphangiogenese, ainsi qu'un systeme d'essai permettant de balayer des composees capables d'induire une croissance de nouveaux vaisseaux lymphatiques.

L9 ANSWER 6 OF 7

PCTFULL COPYRIGHT 2004 Univentio on STN

ACCESSION NUMBER:

1999028469 PCTFULL ED 20020515

TITLE (ENGLISH):

COMPOSITIONS AND METHODS FOR INDUCING GENE EXPRESSION

TITLE (FRENCH):

COMPOSITIONS ET PROCEDES INDUISANT L'EXPRESSION GENIQUE

INVENTOR(S):

GREGORY, Richard, J.;

VINCENT, Karen

PATENT ASSIGNEE(S):

GENZYME CORPORATION;

GREGORY, Richard, J.;

VINCENT, Karen

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9928469	A1	19990610

## DESIGNATED STATES

W:

AU CA IL JP MX NO NZ SG US US AT BE CH CY DE DK ES FI  
FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1998-US25753 A 19981204  
 PRIORITY INFO.: US 1997-60/067,546 19971204  
 US 1998-09/133,612 19980813

ABEN The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

ABFR L'invention concerne des molecules d'acide nucleique de recombinaison qui codent une proteine de transactivation chimere comportant un domaine de liaison d'ADN d'une proteine de liaison d'ADN et un domaine de proteine capable d'induire une activation transcriptionnelle. L'invention concerne egalement des vecteurs viraux et non viraux de recombinaison capables d'infecter et/ou de transfecter et d'assurer l'expression d'une proteine de transactivation chimere biologiquement active dans des cellules mammaliennes. L'invention concerne en outre des lignees cellulaires hotes et des animaux transgeniques non humains capables d'exprimer ladite proteine. L'invention concerne aussi des compositions et des procedes permettant de traiter ou de prevenir les lesions d'origine ischemique associees aux troubles lies a l'hypoxie.

L9 ANSWER 7 OF 7 MEDLINE on STN DUPLICATE 1  
 ACCESSION NUMBER: 1999148331 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 10025464  
 TITLE: Vascular endothelial growth factor is more important than basic fibroblastic growth factor during ischemic wound healing.  
 AUTHOR: Corral C J; Siddiqui A; Wu L; Farrell C L; Lyons D; Mustoe T A  
 CORPORATE SOURCE: Division of Plastic Surgery and Reconstructive Surgery, Northwestern University Medical School, Chicago, Ill, USA.  
 CONTRACT NUMBER: GM-41303 (NIGMS)  
 SOURCE: Archives of surgery (Chicago, Ill. : 1960), (1999 Feb) 134 (2) 200-5.  
 Journal code: 9716528. ISSN: 0004-0010.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
 ENTRY MONTH: 199903  
 ENTRY DATE: Entered STN: 19990326  
 Last Updated on STN: 19990326  
 Entered Medline: 19990318

AB OBJECTIVES: To test the influence of vascular endothelial growth factor ( **VEGF**) on normal and ischemic wounds in a noncontractive dermal

ulcer standardized model in the **rabbit ear** and to **assay** the levels of both **VEGF** and basic fibroblastic growth factor messenger RNA levels in normal and ischemic wounds at different intervals during the healing process. **DESIGN AND INTERVENTIONS:** Dermal ulcers were created in the normal and ischemic ears of 20 anesthetized young female New Zealand white rabbits. Either VEGF 121, VEGF 165 (30 microg per wound), or buffered saline solution alone was applied to each wound and covered. Wounds were harvested at day 7 or 10 and evaluated histologically. Twenty-four similar rabbits were wounded in the same manner and their untreated wounds were harvested at 1, 3, 7, and 10 days after wounding. The wounds were analyzed with reverse transcriptase polymerase chain reaction. **MAIN OUTCOME MEASURES:** Histologic specimens were measured for amount of new epithelium and granulation tissue. Reverse transcriptase polymerase chain reaction was used to determine basic fibroblastic growth factor and VEGF messenger RNA expression. **RESULTS:** Both isoforms of VEGF improved granulation tissue formation in both normal and ischemic wounds with a magnitude similar to other vulnerary agents tested in the past. Vascular endothelial growth factor application had no effect on new epithelium formation. In contrast to basic fibroblastic growth factor, VEGF messenger RNA levels were induced 4 fold by ischemia alone and 6 fold by wounding in both ischemic and normal wounds. **CONCLUSION:** Vascular endothelial growth factor seems to be more important than basic fibroblastic growth factor during ischemic wound healing. Treatment of ischemic wounds with VEGF improves the deficit in wound healing produced by ischemia.

L18 ANSWER 1 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2004:83200 USPATFULL

TITLE: Screening and therapy for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)

INVENTOR(S): Ferrell, Robert E., Pittsburgh, PA, UNITED STATES  
Alitalo, Kari, Helsinki, FINLAND  
Finegold, David N., Pittsburgh, PA, UNITED STATES  
Karkkainen, Marika, Helsinki, FINLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004063656	A1	20040401
APPLICATION INFO.:	US 2003-661740	A1	20030912 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-375248, filed on 16 Aug 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US6133, filed on 26 Mar 1999, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MARSHALL, GERSTEIN & BORUN LLP, 6300 SEARS TOWER, 233 S. WACKER DRIVE, CHICAGO, IL, 60606		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	2972		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.

L23 ANSWER 1 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:306487 USPATFULL  
 TITLE: Vascular endothelial growth factor-2  
 INVENTOR(S): Coleman, Timothy, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215921	A1	20031120
APPLICATION INFO.:	US 2001-921143	A1	20010803 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-223276P	20000804 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	55 Drawing Page(s)	
LINE COUNT:	6836	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are human VEGF-2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF-2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides and polynucleotides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 2 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:251885 USPATFULL  
 TITLE: Vascular endothelial growth factor 2  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Albert, Vivian R., Rockville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Wager, Ruth, Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176674	A1	20030918
APPLICATION INFO.:	US 2002-120377	A1	20020412 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-317600P	20010907 (60)
	US 2001-283391P	20010413 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	133	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	54 Drawing Page(s)	
LINE COUNT:	12110	



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are human **VEGF**-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising **administering** to an animal, preferably a human, an effective amount of one or more **VEGF**-2 antibodies or fragments or variants thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 3 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:250489 USPATFULL  
 TITLE: Vascular endothelial growth factor 2  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Albert, Vivian R., Rockville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Wager, Ruth E., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175274	A1	20030918
APPLICATION INFO.:	US 2002-120414	A1	20020412 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-283385P	20010413 (60)
	US 2002-350366P	20020124 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	133	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	53 Drawing Page(s)	
LINE COUNT:	12105	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are human **VEGF**-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising **administering** to an animal, preferably a human, an effective amount of one or more **VEGF**-2 antibodies or fragments or variants thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 4 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:244377 USPATFULL  
 TITLE: Vascular endothelial growth factor 2  
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Albert, Vivian R., Rockville, MD, UNITED STATES  
 Ruben, Steven M., Olney, MD, UNITED STATES  
 Wager, Ruth E., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170786	A1	20030911
APPLICATION INFO.:	US 2002-120398	A1	20020412 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-283408P	20010413 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	60	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	48 Drawing Page(s)	
LINE COUNT:	11075	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are human **VEGF**-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising **administering** to an animal, preferably a human, an effective amount of one or more **VEGF**-2 antibodies or fragments or variants thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 5 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:38360 USPATFULL  
 TITLE: Vascular endothelial growth factor 2  
 INVENTOR(S): Hu, Jing-Shan, Mountain View, CA, UNITED STATES  
 Cao, Liang, Bethesda, MD, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003028007	A1	20030206
APPLICATION INFO.:	US 2002-84488	A1	20020228 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-623725, filed on 20 Nov 2000, PENDING A 371 of International Ser. No. WO 1999-US5021, filed on 10 Mar 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-42105, filed on 13 Mar 1998, GRANTED, Pat. No. US 6040157 Continuation-in-part of Ser. No. US 1998-107997, filed on 30 Jun 1998, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	47 Drawing Page(s)		
LINE COUNT:	6839		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are human VEGF-2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF-2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides and polynucleotides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 6 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2003:10662 USPATFULL  
 TITLE: Vascular endothelial growth factor 2  
 INVENTOR(S): Hu, Jing-Shan, Sunnyvale, CA, UNITED STATES  
 Rosen, Craig A., Laytonsville, MD, UNITED STATES  
 Cao, Liang, South Horizons, HONG KONG

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003008357	A1	20030109
APPLICATION INFO.:	US 2001-935726	A1	20010824 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-438538, filed on 12 Nov 1999, ABANDONED Division of Ser. No. US 1998-42105, filed on 13 Mar 1998, PATENTED Continuation-in-part of Ser. No. US 1997-999811, filed on 24 Dec 1997, PATENTED Continuation-in-part of Ser. No. US 1995-465968, filed on 6 Jun 1995, PENDING Continuation-in-part of Ser. No. US 1997-824996, filed on 27 Mar 1997, PATENTED Division of Ser. No. US 1994-207550, filed on 8 Mar 1994, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	76		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	47 Drawing Page(s)		
LINE COUNT:	5225		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA (RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 7 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:273361 USPATFULL  
 TITLE: Use of lymphangiogenic agents to treat lymphatic disorders  
 INVENTOR(S): Gravereaux, Edwin C., Brookline, MA, UNITED STATES  
 Silver, Marcy, Bolton, MA, UNITED STATES  
 Yoon, Young-Sup, Watertown, MA, UNITED STATES  
 Isner, Jeffrey M., Weston, MA, UNITED STATES  
 Isner, Linda, Weston, MA, UNITED STATES LR  
 PATENT ASSIGNEE(S): St. Elizabeth's Medical Center of Boston, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151489	A1	20021017
APPLICATION INFO.:	US 2001-970088	A1	20011002 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-237171P	20001002 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David G. Conlin, Dike, Bronstein, Roberts & Cushman, Intellectual Property Practice Group, P. O. Box 9169, Boston, MA, 02209	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	35 Drawing Page(s)	
LINE COUNT:	1803	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for promoting the growth of new lymph vessels (lymphangiogenesis). Generally, such methods include **administering** at least one vascular endothelial factor ( **VEGF**) such as **VEGF**-2. In one embodiment, therapeutic methods for treating **lymphedema** and related disorders in a human patient are disclosed. The **VEGF** can be provided by any suitable means including direct injection of a nucleic acid encoding same or an active fragment thereof. Also provided are pharmaceutical products for promoting lymphangiogenesis as well as a test system for screening compounds capable of inducing new lymph vessel growth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 8 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2000:34403 USPATFULL  
 TITLE: Vascular endothelial growth factor 2  
 INVENTOR(S): Hu, Jing-Shan, Sunnyvale, CA, United States  
 Rosen, Craig A., Laytonsville, MD, United States  
 Cao, Liang, South Horizons, Hong Kong  
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6040157		20000321
APPLICATION INFO.:	US 1998-42105		19980313 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-999811, filed on 24 Dec 1997, now patented, Pat. No. US 5932540 which is a continuation-in-part of Ser. No. US 1997-824996, filed on 27 Mar 1997 And a continuation-in-part of Ser. No. US 1995-465968, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-207550, filed on 8 Mar 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
ASSISTANT EXAMINER:	Saoud, Christine		
LEGAL REPRESENTATIVE:	Human Genome Sciences Inc.		
NUMBER OF CLAIMS:	75		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 47 Drawing Page(s)		
LINE COUNT:	5292		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically self fragments, analogs, or derivatives thereof, and DNA (RNA) encoding such VEGF2 polypeptides. Also provided are

procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 9 OF 15 PCTFULL COPYRIGHT 2004 Univentio on STN  
 ACCESSION NUMBER: 2003097660 PCTFULL ED 20031202 EW 200348  
 TITLE (ENGLISH): VASCULAR ENDOTHELIAL GROWTH FACTOR 2  
 TITLE (FRENCH): FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE 2  
 INVENTOR(S): ROSEN, Graig, A., 22400 Rolling Hill Road,  
 Laytonsville, MD 20882, US [US, US];  
 ALBERT, Vivian, R., 13710 Mills Farm Road, Rockville,  
 MD 20850, US [US, US];  
 RUBEN, Steven, M., 19420 Pyrite Lane, Brookeville, MD  
 20833, US [US, US];  
 WAGER, Ruth, E., 7309 Gold Ring Terrace, Rockville, MD  
 20855, US [US, US]  
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC., 9410 Key West Avenue,  
 Rockville, MA 20850, US [US, US], for all designates  
 States except US;  
 ROSEN, Graig, A., 22400 Rolling Hill Road,  
 Laytonsville, MD 20882, US [US, US], for US only;  
 ALBERT, Vivian, R., 13710 Mills Farm Road, Rockville,  
 MD 20850, US [US, US], for US only;  
 RUBEN, Steven, M., 19420 Pyrite Lane, Brookeville, MD  
 20833, US [US, US], for US only;  
 WAGER, Ruth, E., 7309 Gold Ring Terrace, Rockville, MD  
 20855, US [US, US], for US only  
 AGENT: WALES, Michele, M.\$, Human Genome Sciences, Inc., 9410  
 Key West Avenue, Rockville, MD 20850\$, US  
 LANGUAGE OF FILING: English  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003097660	A1	20031127

DESIGNATED STATES

W:

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC  
 NL PT SE SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US26246 A 20020819

PRIORITY INFO.: US 2002-PCT/US02/11474 20020412

ABEN Disclosed are human **VEGF**-2 antibodies, antibody fragments, or  
 variants thereof. Also provided are processes for producing such  
 antibodies. The present invention relates to methods and compositions  
 for preventing, treating or ameliorating a disease or disorder  
 comprising **administering** to an animal, preferably a human, an

effective amount of one or more **VEGF**-2 antibodies or fragments or variants thereof.

ABFR L'invention concerne des anticorps **VEGF**-2, des fragments d'anticorps ou des variants correspondants. Elle se rapporte également a des procedes de production de ces anticorps. La presente invention concerne en outre des methodes et des compositions destinees a prevenir, traiter ou attenuer une maladie ou un trouble, et consistant a administrer a un animal, de preference un etre humain, une **dose** efficace d'un ou plusieurs anticorps **VEGF**-2 ou des fragments ou variants correspondants.

L23 ANSWER 10 OF 15 PCTFULL COPYRIGHT 2004 Univentio on STN  
 ACCESSION NUMBER: 2002083850 PCTFULL ED 20021107 EW 200243  
 TITLE (ENGLISH): VASCULAR ENDOTHELIAL GROWTH FACTOR 2  
 TITLE (FRENCH): FACTEUR 2 DE CROISSANCE ENDOTHELIALE VASCULAIRE  
 INVENTOR(S): ROSEN, Craig, A., 22400 Rolling Hill Lane,  
 Laytonsville, MD 20882, US [US, US];  
 ALBERT, Vivian, R., 13710 Mills Farm Road, Rockville,  
 MD 20850, US [US, US];  
 RUBEN, Steven, M., 18528 Heritage Hills Drive, Olney,  
 MD 20832, US [US, US];  
 WAGER, Ruth, E., 7309 Gold Ring Terrace, Rockville, MD  
 20855, US [US, US]  
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC., 9410 Key West Avenue,  
 Rockville, MD 20850, US [US, US], for all designates  
 States except US;  
 ROSEN, Craig, A., 22400 Rolling Hill Lane,  
 Laytonsville, MD 20882, US [US, US], for US only;  
 ALBERT, Vivian, R., 13710 Mills Farm Road, Rockville,  
 MD 20850, US [US, US], for US only;  
 RUBEN, Steven, M., 18528 Heritage Hills Drive, Olney,  
 MD 20832, US [US, US], for US only;  
 WAGER, Ruth, E., 7309 Gold Ring Terrace, Rockville, MD  
 20855, US [US, US], for US only  
 AGENT: WALES, Michele, M.\$, Human Genome Sciences, Inc., 9410  
 Key West Avenue, Rockville, MD 20850\$, US  
 LANGUAGE OF FILING: English  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002083850	A2	20021024

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI  
 SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2002-US11405 A 20020412

PRIORITY INFO.:

US 2001-60/283,408 20010413

ABEN Disclosed are human **VEGF**-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder

comprising **administering** to an animal, preferably a human, an effective amount of one or more **VEGF-2** antibodies or fragments or variants thereof.

ABFR La presente invention concerne des anticorps anti VEGF-2 humain, des fragments d'anticorps ou des variants de ceux-ci. La presente invention concerne egalement des procedes pour produire de tels anticorps. En outre, cette invention concerne des methodes et des compositions pour prevenir, traiter ou ameliorer une maladie ou un trouble, lesdites methodes consistant a administrer a un animal, de preference a un etre humain, une quantite efficace d'un ou de plusieurs anticorps anti VEGF-2 ou des fragments ou des variants de ceux-ci.

L23 ANSWER 11 OF 15 PCTFULL COPYRIGHT 2004 Univentio on STN  
 ACCESSION NUMBER: 2002083849 PCTFULL ED 20021107 EW 200243  
 TITLE (ENGLISH): VASCULAR ENDOTHELIAL GROWTH FACTOR 2  
 TITLE (FRENCH): FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE 2  
 INVENTOR(S): ROSEN, Craig, A., 22400 Rolling Hill Lane,  
 Laytonsville, MD 20882, US [US, US];  
 ALBERT, Vivian, R., 13710 Mills Farm Road, Rockville,  
 MD 20850, US [US, US];  
 RUBEN, Steven, M., 18528 Heritage Hills Drive, Olney,  
 MD 20832, US [US, US];  
 WAGER, Ruth, E., 7309 Gold Ring Terrace, Rockville, MD  
 20855, US [US, US]  
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC., 9410 Key West Avenue,  
 Rockville, MD 20850, US [US, US], for all designates  
 States except US;  
 ROSEN, Craig, A., 22400 Rolling Hill Lane,  
 Laytonsville, MD 20882, US [US, US], for US only;  
 ALBERT, Vivian, R., 13710 Mills Farm Road, Rockville,  
 MD 20850, US [US, US], for US only;  
 RUBEN, Steven, M., 18528 Heritage Hills Drive, Olney,  
 MD 20832, US [US, US], for US only;  
 WAGER, Ruth, E., 7309 Gold Ring Terrace, Rockville, MD  
 20855, US [US, US], for US only  
 AGENT: WALES, Michele, M.\$, Human Genome Sciences, Inc., 9410  
 Key West Avenue, Rockville, MD 20850\$, US  
 LANGUAGE OF FILING: English  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002083849	A2	20021024

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI  
 SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2002-US11404 A 20020412

PRIORITY INFO.:

US 2001-60/283,391 20010413

US 2001-60/317,600 20010907

ABEN Disclosed are human **VEGF-2** antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such

antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising **administering** to an animal, preferably a human, an effective amount of one or more **VEGF-2** antibodies or fragments or variants thereof.

ABFR L'invention concerne des anticorps humains VEGF-2, des fragments d'anticorps ou des variants de ceux-ci. L'invention concerne également des procedes de preparation de tels anticorps, ainsi que des procedes et des compositions permettant de prevenir, de traiter ou de soulager une maladie ou un trouble, lesquels consistent a administrer a un animal, de preference a un etre humain, une quantite efficace d'un ou de plusieurs anticorps VEGF-2 ou de fragments ou de variants de ceux-ci.

L23 ANSWER 12 OF 15 PCTFULL COPYRIGHT 2004 Univentio on STN  
 ACCESSION NUMBER: 2002083704 PCTFULL ED 20021107 EW 200243  
 TITLE (ENGLISH): VASCULAR ENDOTHELIAL GROWTH FACTOR 2  
 TITLE (FRENCH): FACTEUR DE CROISSANCE 2, ENDOTHELIAL, VASCULAIRE  
 INVENTOR(S): ROSEN, Craig, A., 22400 Rolling Hill Lane,  
 Laytonsville, MD 20882, US [US, US];  
 ALBERT, Vivian, R., 13710 Mills Farm Road, Rockville,  
 MD 20850, US [US, US];  
 RUBEN, Steven, M., 18528 Heritage Hills Drive, Olney,  
 MD 20832, US [US, US];  
 WAGER, Ruth, E., 7309 Gold Ring Terrace, Rockville, MD  
 20855, US [US, US]  
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC., 9410 Key West Avenue,  
 Rockville, MD 20850, US [US, US], for all designates  
 States except US;  
 ROSEN, Craig, A., 22400 Rolling Hill Lane,  
 Laytonsville, MD 20882, US [US, US], for US only;  
 ALBERT, Vivian, R., 13710 Mills Farm Road, Rockville,  
 MD 20850, US [US, US], for US only;  
 RUBEN, Steven, M., 18528 Heritage Hills Drive, Olney,  
 MD 20832, US [US, US], for US only;  
 WAGER, Ruth, E., 7309 Gold Ring Terrace, Rockville, MD  
 20855, US [US, US], for US only  
 AGENT: WALES, Michele, M.\$, Human Genome Sciences, Inc., 9410  
 Key West Avenue, Rockville, MD 20850\$, US  
 LANGUAGE OF FILING: English  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002083704	A1	20021024

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID  
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD  
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI  
 SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO):

GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO):

AM AZ BY KG KZ MD RU TJ TM

RW (EPO):

AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 TR

RW (OAPI):

BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2002-US11474 A 20020412

PRIORITY INFO.:

US 2001-60/283,385 20010413

US 2002-60/350,366 20020124

ABEN Disclosed are human **VEGF-2** antibodies, antibody fragments, or



variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising **administering** to an animal, preferably a human, an effective amount of one or more **VEGF-2** antibodies or fragments or variants thereof.

ABFR L'invention concerne des anticorps VEGF-2 humains, des fragments d'anticorps ou des variants correspondants, ainsi que des processus de production de ces anticorps. La presente invention a egalement trait a des methodes et a des compositions servant a prevenir, traiter ou ameliorer une maladie ou un trouble. Lesdites methodes consistent a administrer a un animal, de preference, a un etre humain, une quantite efficace d'au moins un anticorps VEGF-2 ou des fragments ou des variants correspondants.

L23 ANSWER 13 OF 15 PCTFULL COPYRIGHT 2004 Univentio on STN  
 ACCESSION NUMBER: 2002029087 PCTFULL ED 20020627 EW 200215  
 TITLE (ENGLISH): USE OF LYMPHANGIOGENIC AGENTS TO TREAT LYMPHATIC DISORDERS  
 TITLE (FRENCH): UTILISATION D'AGENTS LYMPHANGIOGENIQUES POUR LE TRAITEMENT DE TROUBLES LYMPHATIQUES  
 INVENTOR(S): GRAVEREAUX, Edwin, C., 1212 Fifth Avenue, #13E, New York, NY 10029, US;  
 MARCY, Silver, 438 Still River Road, Bolton, MA 01740, US;  
 ISNER, Jeffrey, M., 34 Brenton Road, Weston, MA 02193, US;  
 YOON, Young-sup, 275 Main Street, Apt. #605, Watertown, MA 02472, US  
 PATENT ASSIGNEE(S): ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC., 736 Cambridge Street, Boston, MA 02135, US [US, US]  
 AGENT: BUCHANAN, Robert, L.\$, Dike, Bronstein, Roberts & Cushman - IP Practice Group of Edwards & Angell, LLP, P.O. Box 9169, Boston, MA 02209\$, US  
 LANGUAGE OF FILING: English  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002029087	A2	20020411

## DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL  
 IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG  
 MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
 TM TR TT TZ UA UG UZ VN YU ZA ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US30904 A 20011002

PRIORITY INFO.: US 2000-60/237,171 20001002

ABEN The present invention provides methods for promoting the growth of new lymph vessels (lymphangiogenesis). Generally, such methods include **administering** at least one vascular endothelial factor (**VEGF**) such as **VEGF-2**. In one embodiment, therapeutic methods for treating **lymphedema** and related disorders in a human patient are disclosed. The **VEGF** can be provided by any

suitable means including direct injection of a nucleic acid encoding same or an active fragment thereof. Also provided are pharmaceutical products for promoting lymphangiogenesis as well as a test system for screening compounds capable of inducing new lymph vessel growth.

ABFR L'invention concerne des methodes permettant de favoriser la croissance de nouveaux vaisseaux lymphatiques (lymphangiogenese). D'une maniere generale, de telles methodes consistent a administrer au moins un facteur endothelial vasculaire (VEGF) tel que VEGF-2. Dans un mode de realisation, l'invention concerne des methodes therapeutiques permettant de traiter un lymphoedeme et des troubles associes chez un patient humain. Le VEGF peut etre administre par un moyen approprie quelconque, notamment une injection directe d'un acide nucleique codant celui-ci ou un fragment actif de celui-ci. L'invention concerne en outre des produits pharmaceutiques favorisant la lymphangiogenese, ainsi qu'un systeme d'essai permettant de balayer des composees capables d'induire une croissance de nouveaux vaisseaux lymphatiques.

L23 ANSWER 14 OF 15 PCTFULL COPYRIGHT 2004 Univentio on STN  
 ACCESSION NUMBER: 2002011769 PCTFULL ED 20020711 EW 200207  
 TITLE (ENGLISH): VASCULAR ENDOTHELIAL GROWTH FACTOR 2  
 TITLE (FRENCH): FACTEUR 2 DE CROISSANCE ENDOTHELIALE (VEGF-2)  
 INVENTOR(S): COLEMAN, Timothy, A., 7512 Boxberry Terrace,  
 Gaithersburg, MD 20879, US [US, US]  
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC., 9410 Key West Avenue,  
 Rockville, MD 20850, US [US, US], for all designates  
 States except US;  
 COLEMAN, Timothy, A., 7512 Boxberry Terrace,  
 Gaithersburg, MD 20879, US [US, US], for US only  
 AGENT: WALES, Michele, M.\$, 9410 Key West Avenue, Rockville,  
 MD 20850\$, US  
 LANGUAGE OF FILING: English  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002011769	A1	20020214

## DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
 CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL  
 IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG  
 MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
 TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US24658 A 20010803

PRIORITY INFO.: US 2000-60/223,276 20000804

ABEN Disclosed are human VEGF-2 polypeptides, biologically active,  
 diagnostically  
 or therapeutically useful fragments, analogs, or derivatives thereof,  
 and  
 DNA (RNA) encoding such VEGF-2 polypeptides. Also provided are  
 procedures for  
 producing such polypeptides by recombinant techniques and antibodies and  
 antagonists  
 against such polypeptides. Such polypeptides and polynucleotides may be  
 used

therapeutically for stimulating wound healing and for vascular tissue repair.

Also provided are methods of using the antibodies and antagonists to inhibit

tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy,

rheumatoid arthritis, and psoriasis.

ABFR Cette invention a trait a des polypeptides du VEGF-2, a des fragments, des analogues ou des derives de ceux-ci, biologiquement actifs et des plus utiles en matiere de diagnostic ou de therapie, ainsi qu'a de l'ADN (ARN) codant ces polypeptides du VEGF-2. L'invention porte egalement sur des procedes de production de ces polypeptides, utilisant des techniques de recombinaison, ainsi que sur des anticorps et des

antagonistes de ceux-ci. Ces polypeptides et polynucleotides peuvent avoir une utilisation therapeutique, en l'occurrence pour stimuler la cicatrisation d'une blessure ainsi que pour reparer un tissu vasculaire.

Cette invention concerne, de surcroit, l'utilisation qui est faite des anticorps et des antagonistes susmentionnes pour inhiber une angiogenese

tumorale et, partant, une croissance tumorale, ainsi que pour traiter l'inflammation,

la retinopathie diabetique, la polyarthrite rhumatoide et le psoriasis.

L23 ANSWER 15 OF 15 PCTFULL COPYRIGHT 2004 Univentio on STN  
 ACCESSION NUMBER: 1999046364 PCTFULL ED 20020515  
 TITLE (ENGLISH): VASCULAR ENDOTHELIAL GROWTH FACTOR 2  
 TITLE (FRENCH): FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE 2  
 INVENTOR(S): ROSEN, Craig, A.;  
 CAO, Liang;  
 HU, Jing-Shan  
 PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;  
 ROSEN, Craig, A.;  
 CAO, Liang;  
 HU, Jing-Shan  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9946364	A1	19990916

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE  
 ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
 LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO  
 RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW  
 GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ  
 TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT  
 SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US5021 A 19990310  
 PRIORITY INFO.: US 1998-09/042,105 19980313  
 US 1998-09/107,997 19980630

ABEN Disclosed are human VEGF-2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF-2 polypeptides.

Also provided are procedures for producing such polypeptides by recombinant techniques and

antibodies and antagonists against such polypeptides. Such polypeptides and polynucleotides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.

ABFR L'invention concerne des polypeptides humains du facteur de croissance endothelial vasculaire 2, des fragments, analogues ou derives de ces polypeptides, actifs sur le plan biologique et utiles sur les plans diagnostique et therapeutique, ainsi que l'ADN (ARN) codant ces polypeptides.

L'invention concerne egalement des procedes de production de tels polypeptides a l'aide de techniques de recombinaison, de meme que des anticorps et antagonistes diriges contre de tels polypeptides. On peut utiliser ces polypeptides et polynucleotides de maniere therapeutique pour stimuler la cicatrisation de plaies et dans la reparation de tissus vasculaires. L'invention concerne encore des procedes d'utilisation de ces anticorps et antagonistes, destines a inhiber l'angiogenese de tumeurs et donc la croissance de celles-ci, l'inflammation, la retinopathie diabetique, la polyarthrite rhumatoide et le psoriasis.

09/970088 05/05/2004

=> d his

(FILE 'HOME' ENTERED AT 18:18:15 ON 05 MAY 2004)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS, USPATFULL, PCTFULL' ENTERED AT  
18:18:32 ON 05 MAY 2004

L1 51817 S VEGF  
L2 1786 S (PRODUCTION OR PRODUCE OR FORM OR FORMATION OR GROWTH) (S)LYMP  
L3 5 S LYMPHOSCINTIGRAPHY(S)ASSAY  
L4 5 DUP REM L3 (0 DUPLICATES REMOVED)  
L5 261 S RABBIT(S)EAR(S)ASSAY  
L6 17689 S LYMPHEDEMA OR LYMPHANGIETASIA OR LYMPHANGIOMA OR LYMPHANGIOSA  
L7 85 S L1(P)L2(P)L6  
L8 9 S L1(S)L5  
L9 7 DUP REM L8 (2 DUPLICATES REMOVED)  
L10 7115 S (ADMINISTER? OR ADMINISTRAT? OR GIVE OR DOSE) (S)L1  
L11 113 S L10(P)L2  
L12 40 S L10(P)L2(P)L6  
L13 2 S L12 AND (L5 OR L3)  
L14 2 DUP REM L13 (0 DUPLICATES REMOVED)  
L15 394 S L1(S)L2  
L16 116 S L1(S)L6  
L17 42 S L10 AND L16 AND L15  
L18 41 DUP REM L17 (1 DUPLICATE REMOVED)  
L19 1200 S VEGF(W)2